Summary of Study ST000956

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000657. The data can be accessed directly via it's Project DOI: 10.21228/M8RD64 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000956
Study TitleDetermine metabolomics signatures important for the ability of Streptococus gallolyticus to promote colon cancer cell proliferation
Study SummaryHT29 cells were treated with Sg TX20005 stationary phase, Sg TX20005 exponential phase (negative control), and Sg TX20008 stationary phase (negative control), and media only (baseline control). The cells were washed and aliquoted. One aliquot was pelleted and stored at -80C for metabolomics analysis. DNA was also extracted from the other aliquot for DNA methylation studies.
University of Florida
Last NameXu
First NameYi
Address2121 W. Holcombe Blvd., Houston, TX 77030
Submit Date2018-04-14
Num Groups4
Total Subjects40
Study CommentsSECIM pilot and feasibility, NIH U24 DK097209
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2019-05-15
Release Version1
Yi Xu Yi Xu application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000657
Project DOI:doi: 10.21228/M8RD64
Project Title:Determine metabolomics signatures important for the ability of Streptococus gallolyticus to promote colon cancer cell proliferation
Project Summary:It is now known that intestinal microbiota influences the development of colorectal cancer (CRC). This microbe-CRC connection suggests a potential paradigm shift in the way CRC is detected, treated and managed. Knowledge of specific microbial components involved in the development of CRC is critical to moving this field forward. Among the bacterial species known to associate with CRC, Streptococcus gallolyticus subsp. gallolyticus (Sg), previously known as S. bovis biotype I, stands out as having a strong and well-documented clinical association supported by numerous case reports and surveys over the past several decades. We and others also found that Sg is present in a substantial percentage of CRC patients (up to ~ 74%). We further demonstrated that Sg actively promotes colon tumor growth. These exciting discoveries underscore the importance of Sg in CRC with respect to both function and clinical relevance. Further investigation into the molecular details of the Sg-CRC relationship should have a high priority. Going forward, the key question is how Sg promotes colon tumor development. Data from our lab led us to hypothesize that Sg produces certain metabolites that contribute to its ability to promote cell proliferation. We propose to identify the metabolites important for promoting colon cancer cell proliferation. Our approach is based on two recent findings. We discovered that there are variations among Sg strains in the ability to stimulate host cell proliferation. We also observed that the ability of Sg to promote cell proliferation is bacterial growth phase regulated. Thus by comparing the metabolomics profiles of different Sg strains, and Sg strains from different growth phase co-cultured with colon cancer cells, respectively, we will identify metabolomics signatures that correlate with the ability of Sg to promote cell proliferation. These metabolites will then be investigated in more detail in future studies. In addition, DNA methylation pattern in cells treated with Sg, negative control bacteria and media only will also be compared.
Institute:Texas A&M Health Science Center, Institute of Biosciences and Technology
Department:Center for Infectious and Inflammatory Diseases
Last Name:Xu
First Name:Yi
Address:2121 W. Holcombe Blvd., Houston, TX 77030